Jin Long Chen - Mar 2, 2023 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role: Chief Scientific Officer, Director
Signature: /s/ Valerie Pierce, Attorney-in-fact
Stock symbol: NGM
Transactions as of: Mar 2, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/6/2023, 04:05 PM
Previous filing: Jan 18, 2023
Next filing: Jun 12, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NGM	Common Stock	Award	$0	+64K	+7.04%	$0.00	973K	Mar 2, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NGM	Stock Option (Right to Buy)	Award	$0	+192K		$0.00	192K	Mar 2, 2023	Common Stock	192K	$4.36	Direct	F2
transaction	NGM	Stock Option (Right to Buy)	Award	$0	+175K		$0.00	175K	Mar 2, 2023	Common Stock	175K	$4.36	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
F2	The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.
F3	1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date.